MiNK Therapeutics, Inc. recently filed a Form 424B5, coinciding with a 17.3% drop in its pre-market stock price. The company announced a publication in Frontiers in Immunology highlighting invariant natural killer T (iNKT) cells as a dual-function platform critical for overcoming challenges in solid tumor cell therapy. In related immunology research, a study published in Science Immunology identified cytotoxic T cells with enhanced effector function in tumors, which may have implications for cancer treatments. Additionally, there is ongoing research on an induced pluripotent stem cell (iPSC)-derived CD19/BCMA CAR-NK therapy applied to a patient with systemic sclerosis. Other genetics studies include mitochondrial genome complexity in Erodium stephanianum and reduced T-cell stemness linked to Th17 expansion and graft dysfunction in kidney transplant recipients. Furthermore, a multifactorial feasibility analysis has been conducted on cellular gene therapy access in Africa.